The Association of the British Pharmaceutical Industry (ABPI) have responded to an announcement made today by Health Minister Lord O’Shaughnessy to spend £86 million "to help develop real world medical breakthroughs that will help patients across the NHS."
"It’s important to put significant government investment where it counts, and speeding up patients’ access to new medicines and treatments is one route to healthier lives for us all.
As more and more small and medium-sized innovators join the ABPI, we continue to encourage and advocate ways to make groundbreaking, cost-effective healthcare technologies available as fast as possible. In doing so, patients will not only benefit from improved care, but the NHS will also become more productive and more sustainable in the long term.
Academic Health Science Network’s (ASHNs) are a critical delivery partner for bringing the Accelerated Access Review (AAR) to life, and £39 million of investment is an important first step in pulling industry and the health service together to realise the Review’s ambition.
Turning the rest of the AAR’s recommendations into reality now relies on a full, positive Government response to the Review – and an effective Life Sciences Industrial Strategy.
If we get this right, fostering greater collaboration between innovators, patients, NICE and the NHS can make the UK the world leading hub for Life Sciences."
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.